Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults

• DOI: 10.1111/liv.15856
• Publication Date: 2024-01-31T09:34:41Z
• Authors: Rui Song; Zhao Li; Yingzhi Zhang; Jiahe Tan; Zhiwei Chen
• Keywords: 0303 health sciences; 03 medical and health sciences

Abstract Background & Aims Following the classification of metabolic dysfunction‐associated fatty liver disease (MAFLD), non‐alcoholic (NAFLD) has recently been redefined again as steatotic (MASLD). However, distinctions in characteristics and mortality outcomes between NAFLD, MAFLD MASLD remain unclear. Methods We analysed data from 7519 participants third National Health Nutrition Examination Surveys United States (US) their linked until 2019. Survey weight‐adjusted multivariable Cox proportional model was used to study over three terms. Results The prevalence 18.5%, 19.3% 20.8%, respectively. Most individuals with NAFLD (94.5%) or (100%) can be classified MASLD, while a relatively low percentage those were also diagnosed either (84.1%) (92.7%). During median follow‐up 26.9 years, both associated increased risk all‐cause (adjusted hazard ratio [aHR] 1.18, 95% CI 1.04–1.33 1.19, 1.06–1.34, respectively), this association mainly observed NAFLD−/MASLD+ subgroups. not mortality. all terms an advanced fibrosis (aHR: 1.71–1.81). Subgroup analyses showed that higher for among older adults (≥65 year), non‐Hispanic whites without diabetes. Conclusions Both MALFD risk, but identified greater number compared MAFLD.